Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (191-200 of 435) with videos related to

Pageof 44
Sort By:
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Annals of the Rheumatic Diseases|July 28, 2017
GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studiesWilliam Tillett, Ana-Maria Orbai, Alexis Ogdie, et al.
Clinical Therapeutics|July 9, 2021
Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated DiseasesJuliana Setyawan, Fan Mu, Andres Yarur, et al.
RMD Open|October 1, 2019
Measurement properties of the minimal disease activity criteria for psoriatic arthritisLaura C Coates, Vibeke Strand, Hilary Wilson, et al.
Rheumatology (Oxford, England)|February 16, 2021
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPAREVibeke Strand, Namita Tundia, Martin Bergman, et al.
Annals of the Rheumatic Diseases|March 26, 2013
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trialsVibeke Strand, Roger A Levy, Ricard Cervera, et al.
The Journal of Rheumatology|June 2, 2004
Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readersJohn T Sharp, Frederick Wolfe, Marissa Lassere, et al.
RMD Open|June 7, 2019
Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb studyFrank Buttgereit, Vibeke Strand, Eun Bong Lee, et al.
Journal of Comparative Effectiveness Research|February 27, 2019
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritisVibeke Strand, Iain McInnes, Philip Mease, et al.
Rheumatology (Oxford, England)|March 2, 2016
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisVibeke Strand, Ronald F van Vollenhoven, Eun Bong Lee, et al.
Pageof 44

Showing results (191-200 of 435) with videos related to

Sort By:
Pageof 44
Annals of the Rheumatic Diseases|August 7, 2013
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extensionEdward Keystone, Robert Landewé, Ronald van Vollenhoven, et al.
Annals of the Rheumatic Diseases|July 28, 2017
GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studiesWilliam Tillett, Ana-Maria Orbai, Alexis Ogdie, et al.
Clinical Therapeutics|July 9, 2021
Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated DiseasesJuliana Setyawan, Fan Mu, Andres Yarur, et al.
RMD Open|October 1, 2019
Measurement properties of the minimal disease activity criteria for psoriatic arthritisLaura C Coates, Vibeke Strand, Hilary Wilson, et al.
Rheumatology (Oxford, England)|February 16, 2021
Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPAREVibeke Strand, Namita Tundia, Martin Bergman, et al.
Annals of the Rheumatic Diseases|March 26, 2013
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trialsVibeke Strand, Roger A Levy, Ricard Cervera, et al.
The Journal of Rheumatology|June 2, 2004
Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readersJohn T Sharp, Frederick Wolfe, Marissa Lassere, et al.
RMD Open|June 7, 2019
Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb studyFrank Buttgereit, Vibeke Strand, Eun Bong Lee, et al.
Journal of Comparative Effectiveness Research|February 27, 2019
Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritisVibeke Strand, Iain McInnes, Philip Mease, et al.
Rheumatology (Oxford, England)|March 2, 2016
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritisVibeke Strand, Ronald F van Vollenhoven, Eun Bong Lee, et al.
Pageof 44